North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug

North Immunology is going public in a reverse merger with Aethlon Medical. With eczema as the lead indication, the inflammation and immunology biotech aims to show its bispecific antibody offers efficacy and tolerability advantages over Sanofi’s immune disorder juggernaut, Dupixent. The post North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug appeared first…

Read More

Recortes en servicios de idiomas generan temor a errores médicos, diagnósticos equivocados y muertes

SAN FRANCISCO, California — Organizaciones de salud sin fines de lucro e intérpretes médicos advierten que los recortes federales han eliminado docenas de puestos de trabajadores comunitarios en California, que ayudan a quienes no hablan inglés a obtener cobertura médica y a navegar el sistema de salud. Al mismo tiempo, las personas con dominio limitado…

Read More

Prior authorizations: why they matter and how to navigate the process

Health payers created the prior authorization system as a cost and quality control strategy, ensuring patients receive only the most necessary, evidence-based, cost-effective and quality care. Nevertheless, real-life implementation has shown that prior authorizations often backfire on their original intents, increasing overall care costs beyond what is necessary. It also delays patient care, contributes to…

Read More